Mirati Therapeutics has taken the lid off updated data on KRAS inhibitor adagrasib in colorectal cancer. Having established itself as the front-runner in the space last year, the biotech has presented a new look at the phase 1/2 data that largely reaffirm the earlier findings.

Brickell Biotech is shedding its old name to pursue Fresh Tracks, rebranding to represent its potential evolution into a clinical-stage pharmaceutical company.

What do VC firm Arch Venture Partners, Moderna’s former head of infectious disease vaccines Giuseppe Ciaramella, Ph.D., and Alnylam founding CEO John Maraganore, Ph.D., have in common? They’re all stakeholders in a new biotech launching in the hopes of scaling the heights of the RNA-based therapy market.

BioVie has drummed up investor enthusiasm for its Alzheimer’s disease prospect NE3107, reporting data from an investigator-initiated phase 2 clinical trial that sparked a 39% increase in its share price.

It’s a jungle out there, even for tiny microbes. Bacteria are constantly fighting for survival and resources, duking it out not only with host immune cells but with each other. Perhaps the most formidable warrior of all is Pseudomonas aeruginosa, the multidrug-resistant bacteria associated with hospital-acquired infections like sepsis and pneumonia.

Freenome has already proven its flagship liquid biopsy’s ability to detect cancer as early as possible, thanks to a homegrown platform that uses computational biology and machine learning techniques to analyze each blood sample.

For people who haven’t seen improvements in their symptoms of major depressive disorder with regimens of traditional antidepressants, there is now a new technology to intercede for them.

Sarepta Therapeutics has broken free from an FDA hold—put in place this June—on its phase 2 Duchenne muscular dystrophy (DMD) clinical trial.

In recent years, artificial intelligence developers have changed the face of medicine with algorithms capable of detecting the earliest signs of cancer. Owkin, meanwhile, is taking a slightly different approach with its own cancer-spotting AI.

Iveric Bio is coming for Apellis Pharmaceuticals. Tuesday, the biotech revealed its second late-phase geographic atrophy clinical trial has hit its primary endpoint and outlined plans to file for FDA approval in the eye disease by the end of the first quarter.